Inactive Instrument

GeneNews Ltd Stock Toronto S.E.

CA36870T2065

Biotechnology & Medical Research

StageZero Life Sciences, Ltd. is an integrated healthcare company focused on enhancing the early detection and management of cancer and chronic diseases through advanced molecular diagnostics and clinical interventions. It is developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and for personalized health management, with an initial focus on cancer-related indications. The Company offers early cancer diagnostics and risk stratification via Aristotle, using messenger Ribonucleic Acid (mRNA) technology to identify the molecular signatures of multiple cancer types. Its Care Oncology Clinic provides the COC Protocol, a supervised treatment regimen designed to target multiple metabolic cancer pathways, complementing standard cancer therapies by limiting cancer cell energy supply and use. Additionally, COC offers AVRT, a physician-led telehealth program dedicated to identifying and managing early warning signs of cancer and chronic diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	4.21M 3.74M 3.49M 3.18M 6.01M 405M 6.06M 42.28M 16.38M 207M 15.82M 15.47M 664M	P/E 2021	-2.2x	P/E 2022	-0.39x
Enterprise Value	6M 5.33M 4.97M 4.53M 8.55M 577M 8.63M 60.19M 23.32M 295M 22.52M 22.03M 946M	EV / Sales 2021	3.99x	EV / Sales 2022	1.66x
Free-Float	79.62%	Yield 2021 *	-	Yield 2022	-

13/05/25	StageZero Life Sciences, Ltd. and ElevationMD Introduce Aristotle and AVRT for the Early Detection of Cancer	CI
07/05/25	StageZero Life Sciences Ltd. announced that it expects to receive CAD 2 million in funding	CI
16/12/24	StageZero Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
01/10/24	StageZero Life Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
21/05/24	StageZero Life Sciences Ltd., Q1 2024 Earnings Call, May 21, 2024
16/05/24	StageZero Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/11/23	StageZero Life Sciences Ltd., Q3 2023 Earnings Call, Nov 15, 2023
14/11/23	StageZero Life Sciences Ltd. Partners with My One Medical Source and 1,000+ Medical Access Points in the USA	CI
14/11/23	StageZero Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
07/11/23	StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer Offerings	CI
20/10/23	StageZero Life Sciences	MT
20/10/23	Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer Offerings	CI
15/08/23	StageZero Life Sciences Ltd., Q2 2023 Earnings Call, Aug 15, 2023

01-21	StageZero Announces Partial Revocation of Failure to File Cease Trade Order and Proposed Financing	AQ
15/08/25	StageZero Announces Listing on the NEX Exchange	AQ
25/07/25	StageZero Announces Delisting from the TSX and a Concomitant Application for Listing on the NEX Exchange	AQ
13/05/25	StageZero Life Sciences and ElevationMD Introduce Aristotle and AVRT for the Early Detection of Cancer	AQ
07/05/25	StageZero Announces Partial Revocation of Cease Trade Order and Proposed Financing	AQ

Manager	Title	Age	Since
James Howard-Tripp CEO	Chief Executive Officer	-	10/08/2016
Rebecca Greco IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Rory Riggs CHM	Chairman	72	01/01/2000
James Howard-Tripp CHM	Chairman	-	19/07/2013
Garth MacRae BRD	Director/Board Member	92	01/01/2000

GeneNews Ltd Stock Toronto S.E.

Stocks

CA36870T2065

Biotechnology & Medical Research

Valuation: GeneNews Ltd

Latest news: GeneNews Ltd

Press Releases: GeneNews Ltd

Quotes and Performance

Managers and Directors: GeneNews Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENENEWS LTD	-5.00%	+26.09%	-	-	3.47M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.70%	-0.59%	+52.63%	+128.54%	43.39B
Weighted average by Cap.	+0.12%	-0.84%	+56.96%	+138.26%

	2021	2022
Net sales	5.07M 4.5M 4.2M 3.83M 7.22M 487M 7.29M 50.86M 19.71M 249M 19.03M 18.62M 799M	3.8M 3.37M 3.15M 2.87M 5.41M 365M 5.46M 38.09M 14.76M 187M 14.25M 13.94M 599M
Net income	-7.48M -6.65M -6.21M -5.66M -10.67M -719M -10.77M -75.11M -29.1M -368M -28.1M -27.49M -1.18B	-11.42M -10.14M -9.47M -8.63M -16.27M -1.1B -16.42M -115M -44.39M -561M -42.86M -41.93M -1.8B
Net Debt	-368K -327K -306K -279K -525K -35.42M -530K -3.7M -1.43M -18.11M -1.38M -1.35M -58.12M	1.78M 1.59M 1.48M 1.35M 2.54M 172M 2.57M 17.91M 6.94M 87.69M 6.7M 6.55M 281M